Dati da EMA (European Medicines Agency) - Curati da EPG Health - Ultimo aggiornamento 22 August 2018
Un'Area di apprendimento (AA) di epgonline.org è un'area del sito dedicata a fornire una formazione medica dettagliata e autogestita su una patologia, una malattia o una procedura.
The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology.
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic interstitial lung disease that occurs mostly in older adults, is limited to the lungs and often displays a characteristic imaging and histological appearance. Find out how to diagnose IPF and the latest interventions available for patients living with this burden.
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Nessun argomento correlato Trial clinici trovato
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Background: Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has...
Aggiunto 6 mesi fa
Nessun argomento correlato Linee guida trovato
|Numero prodotto agenzia||EMEA/H/C/002671|
|Data di prima approvazione||13-06-2013|
|Tipo||Medicinale soggetto a prescrizione medica limitativa|
|Titolare dell'autorizzazione all'immissione in commercio||Ratiopharm GmbH|